Company: MBIO
Filing Date: 2025-04-01
Form Type: 424B3
Source: 0001104659-25-030657
Chunk: 128

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-01
Form: 424B3
Chunk 128
---
 December 31, 2024, we reported a stockholders’ deficit of $3.7 million.

The Letter had no immediate effect on our continued
listing on Nasdaq, subject to our compliance with the other continued listing requirements. In accordance with the Nasdaq Listing Rules,
we were provided 45 calendar days, or until April 29, 2024, to submit a plan to regain compliance with the Equity Rule (the
“Compliance Plan”). We submitted our Compliance Plan on April 29, 2024, and the Staff granted our request for an extension
of 180 calendar days through September 9, 2024, to regain compliance with the Equity Rule. We were unable to demonstrate compliance
with the Equity Rule by September 9, 2024.

On September 10, 2024, the Staff formally
notified us that it had determined to delist our securities from Nasdaq based upon our continued non-compliance with the Equity Rule unless
we timely request a hearing before the Nasdaq Hearings Panel (the “Panel”). On September 17, 2024, we requested a hearing
before the Panel, which stayed any further action by Nasdaq at least pending completion of the hearing and the expiration of any extension
that may be granted by the Panel to us following the hearing.

On May 16, 2024, we received a notice (the
“Second Letter”) from the Staff of Nasdaq indicating that the bid price of our common stock had closed below $1.00 per share
for 31 consecutive business days and, as a result, we were not in compliance with Nasdaq Listing Rule 5550(a)(2), which sets
forth the minimum bid price requirement for continued listing on the Nasdaq Capital Market (the “Bid Price Rule”). The Second
Letter from Nasdaq had no immediate effect on the listing of our common stock on Nasdaq. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A),
we were afforded a 180-calendar day grace period, or until November 12, 2024, to regain compliance with the Bid Price Rule. Compliance
can be achieved by evidencing a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days (but
generally not more than 20 consecutive business days) during the 180-calendar day grace period.

The hearing before the Panel occurred on October 29,
2024. By decision dated November 8,